Norstella published a new MMIT use case showing how IDN-level barriers held back an oncology brand and how the team cleared them using IDN-formulary insights.
Public source
Publisher name
Public post
Payer coverage can look strong on paper while access quietly breaks down inside the health system. A new MMIT use case shows how IDN-level barriers, from step therapy an…
Company
Norstella
Norstella is the AI company for biopharma's highest-stakes decisions, from pipeline to patient.
- Industry
- Information Services
- Location
- One Penn Plaza, New York, NY, US
- Company size
- 1,001–5,000 employees
About Norstella
Norstella is the AI company for biopharma's highest-stakes decisions. A global life sciences company trusted by every Top 100 pharma company and industry experts the world over, Norstella unites market-leading brands — Citeline, Evaluate, MMIT, Panalgo, Skipta, and The Dedham Group — turning decision-grade data, insights and expertise into AI you can act on, from pipeline to patient. With the patient always at the center, Norstella is advancing the path to life-changing therapies for patients and providers.
See moreLatest activity
Latest activity from Norstella
14 signals
Presence & Recognition
Norstella is exhibiting at Booth 401 at BioTechX to demonstrate NorstellaLinQ and Norstella AI.
People
Norstella is hiring a Sr. Solutions Consultant for RWD Commercial Strategy & Innovation in the USA, remote.
Presence & Recognition
Norstella is attending the Eagle Alpha Alternative Data Conference in New York on September 10 to discuss biopharma datasets and their use across investment research.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
MMIT
MMIT published a new use case tracing the low adoption of a manufacturer in oncology to barriers within the health systems.
Research & Knowledge
MA360i
MA360i tracks how evidence translates into coverage decisions for ctDNA-MRD in solid-tumor drug development.
Research & Knowledge
Axtria - Ingenious Insights
Axtria - Ingenious Insights reposted its latest whitepaper on Multi-Indication therapies and the ex-US payer landscape.
Research & Knowledge
RxClarity
RxClarity published the first edition of RxClarity Weekly Signals covering oncology developments across clinical data, regulatory decisions, deals, and pipeline moves.
Research & Knowledge
Newristics